Gupon: Angiotensin conversion enzyme inhibitors/angiotensin receptor blockers associated with lower risk of colorectal cancer

Whether angiokine-strain conversion enzyme (ACE) inhibitors and angiotensin receptor blockers will alter the risk of colorectal cancer remains debatableIn a recent study published in the's authoritative journal of cardiovascular, researchers aimed to identify the link between taking these drugs after a baseline colonoscopy negative andthe risk of colorectal cancerthis is a regional retrospective cohort study that recruited patients over the age of 40 who underwent colonoscopies between 2005 and 2013Exclusion criteria include a colorectal examination within 6 monthsdiagnosedcolorectal cancer, past colorectal cancer, inflammatory bowel disease, and previous colonectomyThe main outcome of the study was the diagnosis of colorectal cancer between 6 and 36 months after a colonoscopyThe areas of colorectal cancer are divided into near-end cancer (near end to spleen) and distant cancerThe risk ratio for colorectal cancer, adjusted by ACE inhibitor/angiotensin receptor blockers, was derived by matching score regression on 23 covariates, including patient factors, simultaneous medication, and endoscopic center performanceof 187,897 eligible patients, 30856 (16.4%) of the subjects were given ACE inhibitors/angiotensin blockersBetween 6 and 36 months after a colonoscopy, 454 (0.45%) of the subjects developed colorectal cancer (near-end cancer: 147 people .17.2%)These drugs were associated with a lower risk of developing colorectal cancer less than 3 years after a colonoscopy (adjusted risk ratio was 0.78 (95% CI is 0.64-0.96), but not for colorectal cancer for more than 3 years (adjusted risk ratio was 1.18 (95% CI 0.88-1.57));so that ACE inhibitors/angiotensin receptor blockers reduce the risk of colorectal cancer